LASV inhibitor 3.3 is primarily used in the research and development of antiviral therapies, specifically targeting the Lassa virus (LASV). Its application focuses on inhibiting the replication of the virus, making it a potential candidate for the treatment of Lassa fever, a severe and often fatal hemorrhagic illness. In laboratory settings, it is employed to study viral mechanisms and evaluate its efficacy in blocking viral entry or replication processes. This compound is also explored in preclinical studies to assess its safety, pharmacokinetics, and potential for further development into a therapeutic drug. Its role is critical in advancing antiviral strategies and contributing to the fight against LASV infections.